Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as a sterile solution for subcutaneous use. It stimulates neutrophil production to reduce chemotherapy‑induced neutropenia and supports patients undergoing bone‑marrow transplantation or with congenital neutropenia.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, clinics and pharmacies worldwide, ensuring quality and regulatory compliance with reliable cold‑chain logistics.

Neupogen (filgrastim) is used to stimulate neutrophil recovery in several hematologic conditions. - Chemotherapy‑induced neutropenia: shortens the duration of neutropenia and reduces infection risk. - Aplastic anemia: promotes neutrophil production to improve blood counts. - Bone‑marrow transplantation: enhances engraftment by increasing neutrophil numbers. - Congenital neutropenia: maintains adequate neutrophil levels to prevent recurrent infections.

Filgrastim may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bone pain: aching discomfort, often in the hips or lower back. - Injection site reactions: redness, swelling or mild bruising at the injection site. - Fever: transient elevation of body temperature. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and signs of internal bleeding. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty requiring urgent care. - Severe allergic reactions: rash, swelling, bronchospasm or anaphylaxis.

Before initiating filgrastim therapy, clinicians should consider several precautionary measures to ensure patient safety. - Monitor blood counts: regularly assess neutrophil levels to guide therapy. - Assess spleen size: evaluate for splenomegaly prior to and during treatment. - Use caution in sickle cell disease: increased risk of vaso‑occlusive events. - Avoid in patients with known hypersensitivity to filgrastim or any component of the formulation. - Adjust in renal impairment: consider dose modification in severe renal dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concomitant use of other G‑CSF agents: may cause excessive leukocytosis. - High‑dose corticosteroids: can diminish the neutrophil‑stimulating effect. - Certain chemotherapeutic agents with profound myelosuppression: may require dose adjustments.

Moderate Interactions (Monitor Closely): - Live vaccines: reduced vaccine efficacy; schedule vaccination appropriately. - Antibiotics such as beta‑lactams: monitor for overlapping bone pain. - Immunosuppressants (e.g., cyclosporine): may alter response to filgrastim.